Core Viewpoint - Shandong Xinhua Medical Instrument Co., Ltd. plans to sell up to 5% of its stake in Huajian Medical Holdings Co., Ltd. through public market transactions to focus on core business development and improve asset operation efficiency [1][4]. Group 1: Company Overview - Huajian Medical was established in January 2016 with a registered capital of 1.5 million USD and was listed on the Hong Kong Stock Exchange on July 12, 2019, under the stock code 01931.HK [3]. - As of October 2025, Huajian Medical has issued 1,621,488,096 shares, with the wholly-owned subsidiary Huatuo International holding 443,654,371 shares, accounting for 27.36% of the total issued shares, all of which are non-restricted circulating shares [3][4]. Group 2: Financial Data - As of December 31, 2024, Huajian Medical's total assets were 552,388.34 million, and by June 30, 2025, they increased to 615,913.17 million [2][4]. - The total liabilities rose from 176,269.79 million in 2024 to 263,490.81 million in the first half of 2025 [2][4]. - Owner's equity decreased from 376,118.55 million in 2024 to 352,422.36 million by June 30, 2025 [2][4]. - Operating revenue for the year 2024 was 316,241.48 million, while for the first half of 2025, it was 126,959.46 million [2][4]. - Net profit was reported at 26,603.46 million for 2024 and 3,832.44 million for the first half of 2025 [2][4]. Group 3: Shareholding and Future Plans - After the completion of the share reduction, Huatuo International will still hold more than 5% of Huajian Medical's shares and will continue to enjoy shareholder rights and account for its investment using the equity method [2][4]. - The share sale will be executed based on a reasonable assessment of Huajian Medical's stock price, considering market trends and price fluctuations [1][4].